Genetic Technologies (GENE) has released an update.
Genetic Technologies Limited announces the launch of its groundbreaking GeneType Comprehensive Risk Assessment Test, which assesses over 200 genes to identify individuals’ predisposition to serious diseases, including common cancers, cardiovascular disease, and type 2 diabetes. The test, which includes non-hereditary disease risks and utilizes a simple saliva sample, represents a major advancement in personalized preventative healthcare. The innovative test is poised to transform patient care by enabling tailored interventions and treatment plans.
For further insights into GENE stock, check out TipRanks’ Stock Analysis page.
